Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Study Identifier
PCYC-0227
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Cancer - Other
  • Lung Cancer - Non-Small Cell Lung Cancer (NSCLC)
  • Study Drug
  • Motexafin Gadolinium
  • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.

    Study Locations

    Location
    Status
    Location
    Fountain Valley, California, United States
    Status
    Not applicable
    Location
    Los Angeles, California, United States
    Status
    Not applicable
    Location
    Palm Springs, California, United States
    Status
    Not applicable
    Location
    Columbia, Missouri, United States
    Status
    Not applicable
    Location
    St Louis, Missouri, United States
    Status
    Not applicable
    Location
    Omaha, Nebraska, United States
    Status
    Not applicable
    Showing {first} - {last} of {total} Results